Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?

This publication has 20 references indexed in Scilit:

• The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer
  The Oncologist, 2004
• The value of [18F]fluoro-2-deoxy-?-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment
  Lung Cancer, 2003
• Molecular Whole-Body Cancer Staging Using Positron Emission Tomography: Consequences for Therapeutic Management and Metabolic Radiation Treatment Planning
  Published by Springer Nature ,2003
• Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer
  Nuclear Medicine Communications, 2002
• FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy
  European Journal of Nuclear Medicine and Molecular Imaging, 2002
• 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
  2002
• (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
  2001
• Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography
  New England Journal of Medicine, 2000
• Incidence of local recurrence and second primary tumors in resected stage I lung cancer
  The Journal of Thoracic and Cardiovascular Surgery, 1995
• Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
  The Lancet, 1994